Sézary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/CCL27

Y Masui; M Sugaya; S Kagami; H Fujita; S Yano; M Nagao; M Komine; H Saeki; H Ihn; K Kikuchi; K Tamaki

doi:10.1111/j.1365-2230.2006.02261.x

Sézary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/CCL27

Clin Exp Dermatol. 2007 Jan;32(1):57-9. doi: 10.1111/j.1365-2230.2006.02261.x.

Authors

Y Masui¹, M Sugaya, S Kagami, H Fujita, S Yano, M Nagao, M Komine, H Saeki, H Ihn, K Kikuchi, K Tamaki

Affiliation

¹ Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

PMID: 17305906
DOI: 10.1111/j.1365-2230.2006.02261.x

Abstract

We describe a patient with Sézary syndrome (SS) who was successfully treated with topical steroid and narrowband UVB. Sézary cells in peripheral blood correlated with severity of skin lesions. In addition, serum levels of CCL17 and CCL27 decreased as disease activity improved. These chemokines may be important for the pathogenesis of SS.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Chemokine CCL17
Chemokine CCL27
Chemokines, CC / blood*
Enzyme-Linked Immunosorbent Assay
Female
Humans
Sezary Syndrome / blood
Sezary Syndrome / therapy*
Treatment Outcome
Ultraviolet Therapy* / methods

Substances

CCL17 protein, human
CCL27 protein, human
Chemokine CCL17
Chemokine CCL27
Chemokines, CC